Therapeutics

Combined Multimodal Optimal Imaging and Targeted Gene Silencing Using Stimuli-Transforming Nanotheragnostics, Min Suk Shim, Chang Soo Kim, Yeh-Chan Ahn, Zhongping Chen, and Young Jik Kwon, J. Am. Chem. Soc. 2010, 132,8316-8324. DOI: 10.1021/ja100580y. See Product 10288.

Delivery of NADPH-Cytochrome P450 Reductase Antisense Oligos Using Avidin-Biotin Approach, Venkateswaren C. Pillai, Rekha Yesudas, Imam H. Shaik, Thomas J. Thekkumkara, Ulrich Bickel, Kalkunte S. Srivenugopal, and Reza Mehvar, Bioconjugate Chem. 2010, 21, 203-207. DOI: 10.1021/bc900449b. See Product 10198.

Improved pharmacokinetics and immunogenicity profile of organophosphorus hydrolase by chemical modification with polyethylene glycol, Boris N. Novikov, Janet K. Grimsley, Rory J. Kern, James R. Wild, Melinda E. Wales, Journal of Controlled Release , 2010, on-line 11 June 2010, pg 1-8. DOI: 10.1016/j.jconrel.2010.06.003. See Products 10211, 10260, 10262, 10454.

Monodispersed DOTA-PEG-Conjugated Anti-TAG-72 Diabody Has Low Kidney Uptake and High Tumor-to-Blood Ratios FResulting in Improved Cu PET, Lin Li, Fabio Turatti, Desiree Crow, James R. Bading, Anne-Line Anderson, Erasmus Poku, Paul J. Yazaki, Lawrence E. Williams, Debra Tamvakis, Paul Sanders, David Leong, Andrew Raubitschek, peter J. Hudson, David Colcher, and John E. Shively, J, Nucl Med 2010; 51:1139-1146. DOI: 10.2967/jnumed.109.074153. See Product 10283.

Novel Nanoassemblies Composed of Squalenoyl—Paclitaxel Derivatives: Synthesis, Characterization, and Biological Evaluation, Franco Dosio, L. Harivardhan Reddy, Annalisa Ferrero, Barbara Stella, Luigi Cattel, and Patrick Couvreur, Biconjugate Chem. 2010, 21, 1349-1361. DOI: 10.1021/bc100154g. See Products 10172, 10225.

Synthesis and Preliminary Biological Evaluation of High-Drug-Load Paclitaxel-Antibody Conjugates for Tumor-Targeted Chemotherapy, Sherly Quiles, Kevin P. Raisch, Leisa L. Sanford, James A. Bonner, and Ahmad Safavy, J Med. Chem. 2010, 53, 586-594. DOI: 10.1021/jm900899g. See Products 10067, 10401.

Controlling HBV Replication in Vivo by Intravenous Administration of Triggered PEGylated siRNA-Nanoparticles, Sergio Carmona, Michael R. Jorgensen, Soumia Kolli, Carol Crowther, Felix H. Salazar, Patricia L. Marion, Masato Fujino, Yukikazu Natori, Maya Thanou, Patrick Arbuthnot, and Andrew D. Miller, Molecular Pharmacutics Vol. 6, No. 3, 706-717. DOI: 10.1021/mp800157x. See Product 10213.

Effect of PEGylation of N-WASP181-200 on the Inhibitory Potency for Renal Aminoglycoside Accumulation, Kenju Fujii, Junya Nagai, Takeshi Sawada, Ryko Yumoto, and Mikihisa Takano, Bioconjugate Chem. 2009, 20, 1553-1558. DOI: 10.1021/bc900094g. See Product 10313.

Efficient Transfection of Blood-Brain Barrier Endothelial Cells by Lipoplexes and Polyplexes in the Presence of Nuclear Targeting NLS-PEG-Acridine Conjugates, Hongwei Zhang, Anton Mitin, and Sergui V. Vinogradov, Bioconjugate Chem. 2009, 20, 120-128. DOI: 10.1021/bc8003414. See Product 10284.

In vitro and in vivo evaluation of a non-carbohydrate targeting platform for lysosomal proteins, James E. Stefano, Lihui Hou, Denise Honey, Josephine Kyazike, Anna Park, Qun Zhou, Clark Q. Pan, Tim Edmunds, Journal of Controlled Release 135 (2009) 113-118. DOI: 10.1016/j.jconrel.2008.12.006. See Product 10184.

Laser-Activated Gene Silencing via Gold Nanoshell-siRNA Conjugates, Gary B Braun, Alessia Pallaoro, Guohui Wi, Dimitris Missirlis, Joseph A. Zasadzinski, Matthew Tirrell, and Norbert O. Reich, ACS Nano, Vol. 3, No. 7, 2007-2015, 2009. pg 2014. DOI: 10.1021/nn900469q. See Product 10260.

Magnetic Separation of Melenoma-Specific Cytoxic T Lymphocytes from a Vaccinated Melanoma Patients’s Blood Using MHC/Peptide Complex-Conjugated Bacterial Magnetic Particles, Masayuki Takahashi, Yasuto Akiyama, Junpei Ikezumi, Takeshi Nagata, Tomoko Yoshino, Akira Iizuka, Ken Yamaguchi, and Tadashi Matsunaga, Bioconjugate Chem. 2009, 20, 304-309. DOI: 10.1021/bc800398d. See Product 10198.

Molecular Dendritic Transporter Nanoparticle Vectors Provide Efficient Intracellular Delivery of Peptides, Sharon K. Hamilton and Eva Harth, ACS Nano Vol. 3, No. 2, 402-410, 2009. Pg 408. DOI: 10.1021/nn800679z. See Products 10210, 10211.

Pharmacokinetics and Tumor Disposition of PEGylated Methotrexate Conjugated Poly-L-lysine Dendrimers, Lisa M. Kaminskas, Brian D. Kelly, Victoria M. McLeod, Ben J. Boyd, Guy Y. Krippner, Elizabeth D. Williams, and Christopher J. H. Porter, Molecular Pharmaceutics, Vol. 6, No. 4, 1190-1204, 2009. DOI: 10.1021/mp900049a. See Products 10339, 10402, 10928, 10262, 10304, 10920.

TAT Peptide and Its Conjugate: Proteolytic Stability, Jacob Grunwald, Tomas Rejtar, Rupa Sawant, Zhouxi Wang, and Vladimir P. Torchilin, Bioconjugate Chem. 2009, 20, 1531-1537. DOI: 10.1021/bc900081e. See Product 10924.

The impact of molecular Weight and PEG Chain Length on the Systemic Pharmacokinetics of PEGylated Poly L-Lysine Dendrimers, Lisa M. Kaminskas, Ben J. Boyd, Peter Karellas, Guy Y. Krippner, Romina Lessene, Brian Kelly, and Christopher J. H. Porter, Molecular Pharmaceutics, Vol. 5, No. 3, 449-463, 2008. DOI: 10.1021/mp7001208. See Products 10211, 10262.

Potent D-peptide inhibitors of HIV-1 entry, Brett D. Welch, Andrew P. VanDemark, Annie Heroux, Christopher P. Hill, and Michael S. Kay, PNAS, Vol. 104, No. 43, October 23, 2007. DOI: 10.1073/pnas.0708109104. See Products 10246, 10260.

Effects of linker variation on the in vitro and in vivo characteristics of an In-labeled RGD peptide, Ingrid Dijkgraaf, Shuang Liu, John A.W. Kruijtzer, Annemieke C. Soede, Wim J.G. Oyen, Rob M.J. Liskamp, Frans H.M. Corstens, Otto C. Boerman, Nuclear Medicine and Biology 34 (2007) 29-35. DOI: 10.1016/j.nucmedbio.2006.10.006. See Product 10250.

Improved Biodistribution and Radioimmunoimaging with Poly(ethylene glycol)-DOTA-Conjugated Anti-CEA Diabody, Lin li, Paul J. Yazaki, Anne-Line Anderson, Desiree Crow, David Colcher, Anna M. Wu, Lawrence E. Williams, Jeffrey Y.C. Wong, Andrew Raubitschek, and John E. Shively, Bioconjugate Chem. 2006, 17, 68-76. DOI: 10.1021/bc0502614. See Product 10284.

Species Differences of Bombesin Analog Interactions with GRP-R Define the Choice of Animal Models in the Development of GRP-R-Targeting Drugs, Theodosia Maina, PhD; Berthold A. Nock, PhD; Hanwen Zhang, Anastasia Nikolopoulou, Msci, Beatrice Waser, PhD; Jean Claude Reubi, MD; and Helmut R. Maecke, PhD; J, Nucl Med 2005; 46:823-830. See Product 10213.